Rejected from Nature Reviews Cancer? Where to Submit Your Review Next

The right next venue depends on whether your review is biological or clinical, and whether you need open access. The table below maps the realistic options. Every journal listed accepts unsolicited review work in some form, which Nature Reviews Cancer largely does not.

Source: journal author pages and editorial-process pages (accessed June 2026); APCs in USD where published; Clarivate JCR 2024 for citation metrics.

A few decisions hide inside that table. Trends in Cancer and Seminars in Cancer Biology are the closest substitutes when your work is genuinely a field-level synthesis but did not fit Nature Reviews Cancer's calendar. Nature Reviews Clinical Oncology is the move if the synthesis is clinical rather than biological. Molecular Cancer and npj Precision Oncology trade some prestige for a real submission system and open access.

Cancer Discovery and Nature Cancer are the homes if you decide the work is better as primary research or a data-backed perspective rather than a review.

To set expectations on standing, here is how these venues compare against Nature Reviews Cancer on citation metrics and whether they accept unsolicited work. The metric is a weak proxy for fit, but it tells you how far you are stepping in prestige terms.

Source: Clarivate JCR 2024; journal author pages (accessed June 2026).

There is no portfolio-transfer button for a declined Nature Reviews Cancer proposal, because nothing entered peer review. So the action plan here is a repitch ladder, plus a reframe option that is often the strongest play. Here is what to do next, in order.

Step 1, repitch as a review where it fits. If the topic is biological and timely, send a fresh synopsis to Trends in Cancer first (it is concise and takes unsolicited reviews), then Seminars in Cancer Biology if a relevant thematic issue is open. If the topic is clinical, send the synopsis to Nature Reviews Clinical Oncology before anything else. Write a new pitch for each venue rather than forwarding the Nature Reviews Cancer one; each journal weighs scope and framing differently.

Step 2, go open access if you need speed and certainty. Molecular Cancer and npj Precision Oncology both run standard submission systems with first decisions usually inside 4 to 8 weeks, so you are not waiting on a commissioning slot. This is the practical route if the proposal was declined for timeliness and you cannot afford another long pitch cycle.

Step 3, reframe the work entirely. A review proposal that the editors found too narrow for a field-level synthesis is often a strong Perspective (an argued position rather than a survey) or, if you hold unpublished data, a primary research or translational article. Cancer Discovery and Nature Cancer JIF 28.5 both publish data-driven perspectives next to primary research. Reframing the same evidence around one central argument is frequently the highest-yield move after a declined review proposal, because it sidesteps the commissioning bottleneck altogether.

In our pre-submission review work with Nature Reviews Cancer submissions, the proposals and draft reviews we screen cluster into a small set of patterns that predict a declined synopsis. Our review of these proposals shows the same failure modes repeat across subfields, and most are testable before you pitch anywhere else.

The synopsis describes coverage instead of an argument. This is the pattern we see most often in Nature Reviews Cancer proposals we review. The 200-word abstract lists what the field has found, which labs found it, and how much literature exists, but never states the interpretive claim the review will make. Nature Reviews Cancer wants a synthesis that reframes the field, not a comprehensive catalog.

When the abstract reads as a table of contents rather than a thesis, editors decline because they cannot see what a reader gains beyond a literature search. Rewrite the abstract so the first two sentences state the argument the review will defend, then test it: if a competitor could write the same synopsis from a PubMed search, it is coverage, not synthesis.

The author-authority case is thin for the exact topic. Across our Nature Reviews Cancer pre-submission reviews, roughly a quarter of declined proposals trace to an author list whose primary-research record does not sit squarely in the review's subject. Editors specifically screen for whether the proposing authors have published the foundational primary work in that exact area, and they invite reviewers on that basis.

A proposal from a strong cancer biologist writing outside their core subfield reads as a generalist survey. Check the author list and key references against the topic: if your own first-author primary papers are not among the proposed key references, the authority case needs strengthening or the topic needs narrowing to where your record is deepest.

The timeliness window is already closed. Nature Reviews Cancer plans a commissioning calendar, and a proposal that overlaps a recently published or already-commissioned review is declined on timing rather than quality. We flag this when the key-references list shows the most recent reviews on the topic are under two years old and from the same venue or its siblings.

Before pitching, scan the last two years of Nature Reviews Cancer and Nature Cancer for the same scope. If a close review exists, either sharpen the angle to a genuinely uncovered facet or move to a venue with an open thematic issue, such as Seminars in Cancer Biology.

The display items signal a primary paper, not a review. Nature Reviews Cancer reviews are built around conceptual schematics that organize a field, typically 5 to 7 display items. When a proposed outline leans on original data figures, unpublished results, or method-heavy panels, the editors read it as a primary research paper in review clothing.

If your strongest figures are your own unpublished data, that is the clearest signal to reframe the work for Nature Cancer, Cancer Discovery, or Molecular Cancer rather than repitching it as a review. Audit your planned figures: schematics and field-organizing models belong in a review; novel data panels belong in a research article.

The scope is specialist, not field-level. A genuine, useful review that covers one mechanism, one pathway, or one tumor type in depth is often too narrow for Nature Reviews Cancer's general cancer-research audience, even when it is excellent. We see this when the proposed sections all sit inside a single subfield with no bridge to broader cancer biology.

This is not a flaw to fix so much as a fit signal: Trends in Cancer and Seminars in Cancer Biology actively want focused, expert reviews at exactly this resolution, so the same proposal often lands well there with only a reframed abstract.

Be honest about which problem you actually have, because the commissioned model changes the math. If the proposal was declined for fit or timeliness, the manuscript itself may be fine and the fix is choosing a venue that accepts unsolicited reviews. Do not blast the identical synopsis down the list. Each journal weighs biological versus clinical framing, scope, and open-access posture differently, so a recycled pitch that ignores those differences gets declined for the same reasons twice.

If the proposal was declined because the synopsis described coverage rather than an argument, that is real work, not a formatting pass. Rewriting the abstract around a thesis, and pruning the outline to support that thesis, is the difference between a review that reframes a field and a survey any AI summary could assemble. And if your strongest material is unpublished data, the most efficient path is usually not another review pitch at all. Reframe the work as a research article or perspective and skip the commissioning queue entirely.

Submit a fresh review proposal if the decline cited scope or timeliness, your argument is genuinely field-level, and you can name a journal whose calendar has room for it. In that case the work is sound and the fix is the target.

Think twice if the same idea has been declined twice on fit, or if a close review already ran in the last two years. Repitching unchanged invites the same outcome. Fix first: sharpen the angle to a facet no recent review covered, or reframe the evidence into a Perspective or research article. The Nature Reviews Cancer profile and sibling guides can help you check the standing and scope of each next target before you commit a cycle.